Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7901 to 7950 of 8905 results

  1. Unstable angina and NSTEMI: early management (CG94)

    This guideline has been updated and replaced by NICE guideline NG185.

    Withdrawn guideline

  2. Neuropathic pain in adults: pharmacological management in non-specialist settings (CG96)

    This guidance has been updated and replaced by NICE guideline CG173.

    Withdrawn guideline

  3. Low back pain in adults: early management (CG88)

    This guidance has been updated and replaced by NICE guideline NG59.

    Withdrawn guideline

  4. Eating disorders in over 8s: management (CG9)

    This guidance has been updated and replaced by NICE guideline NG69.

    Withdrawn guideline

  5. Depression in adults: recognition and management (CG90)

    This guideline has been updated and replaced by NICE guideline on depression in adults: treatment and management (NG222).

    Withdrawn guideline

  6. Psychosis and schizophrenia: management (CG82)

    This guidance has been updated and replaced by NICE guideline CG178. This guideline updates and replaces NICE guideline CG1.

    Withdrawn guideline

  7. Glaucoma: diagnosis and management (CG85)

    This guidance has been updated and replaced by NICE guideline NG81.

    Withdrawn guideline

  8. Coeliac disease: recognition and assessment (CG86)

    This guidance has been updated and replaced by NICE guideline NG20.

    Withdrawn guideline

  9. Type 2 diabetes: The management of type 2 diabetes (CG87)

    This guidance has been updated and replaced by NICE guideline NG28.

    Withdrawn guideline

  10. Asfotase alfa for treating paediatric-onset hypophosphatasia (HST6)

    This guidance has been updated and replaced by NICE highly specialised technologies guidance 23.

    Withdrawn guidance

  11. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (HST3)

    This guidance has been updated and replaced by NICE highly specialised technologies guidance 22.

    Withdrawn guidance

  12. Elosulfase alfa for treating mucopolysaccharidosis type IVa (HST2)

    This guidance has been updated and replaced by NICE’s highly specialised technologies guidance on elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19).

    Withdrawn guidance

  13. Smoking: harm reduction (QS92)

    This quality standard has been updated and replaced by NICE quality standard 207.

    Withdrawn quality standard

  14. Obesity in children and young people: prevention and lifestyle weight management programmes (QS94)

    This quality standard has been updated and replaced by NICE quality standard 212.

    Withdrawn quality standard

  15. Nutrition: improving maternal and child nutrition (QS98)

    January 2025: This quality standard has been stood down. Quality statements on maternal and child nutrition can be found in the NICE quality standards on antenatal care and postnatal care.

    Withdrawn quality standard

  16. Developing NICE guidelines: how to get involved (PMG22)

    October 2018: This process guide has been updated. The updated version can be found in the tools and resources for developing NICE guidelines: the manual.

    Withdrawn guide

  17. Process manual for the endorsement of guidance and quality standard support resources (PMG29)

    The endorsement programme is now closed and no new applications are being accepted. Information about existing endorsed resources, are available on the endorsement webpage. Please email endorsement@nice.org.uk if you have any queries.

    Withdrawn guide

  18. Medicines optimisation: key therapeutic topics – Integrated process statement (PMG13)

    February 2022: we have withdrawn our medicines optimisation: key therapeutic topics. We have taken this decision after reviewing the wide range of services we currently provide, so we can focus on delivering the priorities outlined in our 5-year strategy. If you have any queries, please contact nice@nice.org.uk.

    Withdrawn guide

  19. Process guide for adoption support resources for health technologies (PMG23)

    This process and methods guide has been withdrawn.

    Withdrawn guide

  20. Medical technologies evaluation programme methods guide (PMG33)

    This medical technologies evaluation programme methods guide has been replaced by the NICE HealthTech programme manual.

    Withdrawn guide

  21. Into practice guide (PMG30)

    This guide has been updated and replaced by practical steps to improving the quality of care and services using NICE guidance.

    Withdrawn guide

  22. Health technology evaluations: interim methods and process guide for the proportionate approach to technology appraisals (PMG40)

    This interim methods and process guide for the proportionate approach to technology appraisals has been incorporated into NICE health technology evaluations: the manual.

    Withdrawn guide

  23. Medical technologies evaluation programme process guide (PMG34)

    This medical technologies evaluation programme process guide has been replaced by the NICE HealthTech programme manual.

    Withdrawn guide

  24. Key therapeutic topics – Medicines management options for local implementation: Interim process statement (PMG7)

    February 2022: we have withdrawn our medicines optimisation: key therapeutic topics. We have taken this decision after reviewing the wide range of services we currently provide, so we can focus on delivering the priorities outlined in our 5-year strategy. If you have any queries, please contact nice@nice.org.uk.

    Withdrawn guide

  25. Stereotactic radiosurgery for trigeminal neuralgia using the gamma knife (IPG85)

    Interventional procedures, IPG85 - Issued: August 2004 --> This guidance has been updated and replaced by NICE HealthTech guidance 608. 

    Withdrawn guidance

  26. Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]

    In development Reference number: GID-TA10745 Expected publication date:  17 July 2024

    Technology appraisal guidance
    In development

  27. Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over (TA138)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Withdrawn guidance

  28. The clinical and cost effectiveness of pegylated interferon alpha 2a and alpha 2b for hepatitis C (TA14)

    This guidance has been replaced by NICE technology appraisal guidance 75.

    Withdrawn guidance

  29. Infliximab for subacute manifestations of ulcerative colitis (TA140)

    This guidance has been updated and replaced by NICE technology appraisal guidance 329.

    Withdrawn guidance

  30. Abatacept for the treatment of rheumatoid arthritis (TA141)

    This appraisal has been updated and replaced by NICE technology appraisal guidance 195.

    Withdrawn guidance

  31. Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia (TA142)

    This guidance has been replaced by NICE technology appraisal guidance 323.

    Withdrawn guidance

  32. Adalimumab, etanercept and infliximab for ankylosing spondylitis (TA143)

    This guidance has been updated and replaced by NICE technology appraisal guidance 383.

    Withdrawn guidance

  33. Rimonabant for the treatment of overweight and obese adults (TA144)

    This appraisal has been withdrawn. This is because the marketing authorisation for rimonabant was withdrawn on 16 January 2009.

    Withdrawn guidance

  34. Bevacizumab for the first-line treatment of metastatic breast cancer (TA147)

    This appraisal has been updated and replaced by NICE technology appraisal 214.

    Withdrawn guidance

  35. Methylphenidate for the treatment of attention deficit hyperactivity disorder in children and adolescents (TA13)

    This guidance has been replaced by NICE technology appraisal guidance 98 [Replaced by NICE guideline NG87].  

    Withdrawn guidance

  36. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (TA130)

    This guidance has been updated and replaced by NICE technology appraisal guidance 375.

    Withdrawn guidance

  37. Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years (TA131)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Withdrawn guidance

  38. Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia (TA132)

    This guidance has been updated and replaced by NICE technology appraisal guidance 385.

    Withdrawn guidance

  39. Omalizumab for severe persistent allergic asthma (TA133)

    This guidance has been replaced by NICE technology appraisal guidance 278.

    Withdrawn guidance

  40. Certolizumab pegol for the treatment of rheumatoid arthritis (TA186)

    This guidance has been updated and replaced by NICE technology appraisal guidance 375.

    Withdrawn guidance

  41. Sorafenib for the treatment of advanced hepatocellular carcinoma (TA189)

    This guidance has been replaced by NICE technology appraisal guidance 474.

    Withdrawn guidance

  42. Alzheimer's disease (mild to moderate) - donepezil, rivastigmine and galantamine (TA19)

    This guidance has been replaced by NICE technology appraisal guidance 111.

    Withdrawn guidance

  43. Denosumab for the treatment of therapy-induced bone loss in non-metastatic prostate cancer (terminated appraisal) (TA194)

    This guidance has been updated and replaced by NICE guideline CG175.

    Withdrawn guidance

  44. Autologous cartilage transplantation for full thickness cartilage defects in knee joints (TA16)

    This guidance has been replaced by NICE technology appraisal guidance 89 [Replaced by NICE technology appraisal guidance 477].

    Withdrawn guidance

  45. Erlotinib for the treatment of non-small-cell lung cancer (TA162)

    This guidance has been updated and replaced by NICE technology appraisal guidance 374.

    Withdrawn guidance

  46. Febuxostat for the management of hyperuricaemia in people with gout (TA164)

    This guidance has been updated and replaced by NICE guideline NG219.

    Withdrawn guidance

  47. Cochlear implants for children and adults with severe to profound deafness (TA166)

    This guidance has been updated and replaced by NICE technology appraisal guidance 566.

    Withdrawn guidance

  48. Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck (TA172)

    This guidance has been updated and replaced by NICE technology appraisal guidance 473.

    Withdrawn guidance

  49. Gefitinib for the second-line treatment of locally advanced or metastatic non-small-cell lung cancer (terminated appraisal) (TA175)

    This guidance has been updated and replaced by NICE technology appraisal guidance 374.

    Withdrawn guidance

  50. Cetuximab for the first-line treatment of metastatic colorectal cancer (TA176)

    This guidance has been updated and replaced by NICE technology appraisal guidance 439.

    Withdrawn guidance